LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Închisă

SectorSănătate

7.27 0.55

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

7.19

Maxim

7.4

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.75 50.102
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-31.22% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-23M 360M
Deschiderea anterioară	6.72
Închiderea anterioară	7.27

Sentimentul știrilor

By Acuity

50%

138 / 344 Clasament în Healthcare

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 mai 2026, 21:33 UTC

Câștiguri

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mai 2026, 21:00 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mai 2026, 20:18 UTC

Câștiguri

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mai 2026, 21:29 UTC

Acțiuni populare

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mai 2026, 21:08 UTC

Câștiguri

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mai 2026, 21:02 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mai 2026, 20:59 UTC

Achiziții, Fuziuni, Preluări

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mai 2026, 20:55 UTC

Câștiguri

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 mai 2026, 20:48 UTC

Câștiguri

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mai 2026, 20:45 UTC

Câștiguri

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mai 2026, 20:34 UTC

Achiziții, Fuziuni, Preluări

Webster Financial Stockholders Approve Sale to Banco Santander

27 mai 2026, 20:32 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mai 2026, 20:32 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mai 2026, 20:32 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mai 2026, 20:30 UTC

Câștiguri

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mai 2026, 20:30 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mai 2026, 20:22 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:16 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:13 UTC

Câștiguri

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mai 2026, 20:13 UTC

Câștiguri

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mai 2026, 20:13 UTC

Câștiguri

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mai 2026, 20:12 UTC

Câștiguri

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mai 2026, 20:12 UTC

Câștiguri

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-31.22% jos

Prognoză pe 12 luni

Medie 5 USD -31.22%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

138 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.